- 學位論文
Monascus purpureus NTU 568 發酵產物對酒精性肝損傷及肝臟纖維化之保健功效評估
Protective effect of Monascus purpureus NTU 568-fermented products against alcoholic liver disease and hepatic fibrosis
若您是本文的作者，可授權文章由華藝線上圖書館中協助推廣。
摘要
Monascus purpureus NTU 568 之發酵代謝產物具有廣泛的生物活性，包括抑制腫瘤、調節高三酸甘油酯、抗氧化及抗發炎等活性。然而，酒精性肝損傷的病理機制並未清楚。因此在本研究中，利用慢性酒精性肝損傷的小鼠作為實驗模式，以評估 M. purpureus NTU 568 發酵紅麴米 (Monascus-fermented red mold rice, RMR) 及紅麴山藥 (Monascus-fermented red mold dioscorea, RMD) 保護肝臟的功效。此實驗模式中，分別餵食酒精誘導肝損傷的小鼠紅麴米及紅麴山藥 307.5 mg/kg (一倍劑量)、615.0 mg/kg (兩倍劑量) 及 1537.5 mg/kg (五倍劑量) 持續餵食五周。餵食紅麴米及紅麴山藥組均顯著降低血清中天門冬胺酸轉胺酶 (aspartate aminotransferase, AST)、丙胺酸轉胺酶 (alanine aminotransferase, ALT)、瘦體素 (lepatin) 及肝臟中三酸甘油酯 (triglyceride, TG)、總膽固醇 (total cholesterol, TC) 及游離脂肪酸 (free fatty acid, FFA) 的累積，並且可提高血清中脂聯素 (adiponectin) 與肝臟中酒精去氫酶 (alcohol dehydrogenase, ADH) 含量。紅麴米及紅麴山藥也可進一步的提升肝臟抗氧化功能、減低肝細胞傷害 (脂肪肝) 並且降低肝臟的促發炎細胞激素含量。重複性的慢性或急性肝臟損傷會造成肝臟一再修復，並且導致肝纖維化疾病產生。而此疾病與活化肝星狀細胞 (hepatic stellate cell, HSCs) 增生及細胞外基質 (extracellular matrixc, ECM) 的累積具有相當大的關連性。以紅麴發酵產物中分離出之 ankaflavin (AK) 及 monascin (MS) 進行體外細胞實驗，不但有效提升 HepG2 細胞中過氧化小體增生劑活化接受體γ (peroxisome proliferator-activated receptor-γ) 含量並降低酒精引起的固醇調節元件結合蛋白 (sterol regulatory element-binding proteins-1) 和 TG 上升，同時也可以抑制肝臟的纖維化。實驗發現利用 AK 及 MS (15 及 30 μM)，可有效抑制 HSC-T6 細胞的 Akt/nuclear factor (NF)-κB 及 p38 mitogen-activated protein kinase (MAPK) 分子路徑。同時於 AK (30 μM) 及 MS (30 μM) 濃度下可有效抑制細胞生長並導致細胞凋亡，與控制組相比細胞存活率分別為： 80.2 ± 5.4% 及 62.8 ± 8.2%; P < 0.05。導致細胞週期停滯於 G1 期 (G1 期 AK 與 MS 百分比分別為： 76.1 ± 2.9% 及 79.9 ± 1.8%，控制組為： 65.9 ± 4.9% (P < 0.05)。由以上實驗發現紅麴發酵產物可以有效降低氧化壓力、發炎反應、脂肪肝及抑制肝臟星狀細胞的增生而達到保護酒精性肝疾病的功效。
並列摘要
Monascus purpureus NTU 568 fermented products are reported to exhibit a wide variety of biological effects, including antitumor, antihypertriglyceridemia, antioxidation, and anti-inflammatory activities. However, its role in the pathogenesis of alcoholic liver disease remains obscure. In this study, the hepatoprotective effects of Monascus-fermented red mold rice (RMR) and Monascus-fermented red mold dioscorea (RMD) were evaluated in vivo using chronic alcohol-induced mice as an experimental model. The alcohol-induced mice were orally treated with RMR or RMD at 307.5 mg/kg (1-fold), 615.0 mg/kg (2-fold), and 1537.5 mg/kg (5-fold) for 5 weeks, whereas controls received vehicle only. Treatment with RMR or RMD significantly attenuated the increased level of serum transaminases (AST, aspartate aminotransferase and ALT, alanine aminotransferase), leptin and hepatic triglyceride (TG), total cholesterol (TC), free fatty acid (FFA) accumulation, and increased serum adiponectin, hepatic alcohol dehydrogenase (ADH) levels. Furthermore, RMR and RMD elevates hepatic antioxidant ability that reduced hepatic cell damage (steatosis) and decreased tissue inflammatory cytokine levels. Hepatic fibrosis represents a wound-healing process in the liver and a response to acute or chronic hepatic injuries observed in diseases. The increased proliferation of activated hepatic stellate cells (HSCs) is associated with hepatic fibrosis and excessive extracellular matrix (ECM)-protein production. In this study, we isolated the compounds, ankaflavin (AK) and monascin (MS) from M. purpureus-fermented metabolites that were not only significantly induced peroxisome proliferator-activated receptor-γ expression and concomitant suppression of ethanol-induced elevation of sterol regulatory element-binding proteins-1 and TG in HepG2 cells but also inhibited hepatic fibrosis in vitro. We examined the inhibitory effects of the AK and MS (15 and 30 μM), on the Akt/nuclear factor (NF)-κB and p38 mitogen-activated protein kinase (MAPK) signaling pathways in HSC-T6 (activated hepatic stellate cell line). AK and MS (30 μM, 30 μM) induced apoptosis and significantly inhibited cell growth (cell viabilities: 80.2 ± 5.4% and 62.8 ± 8.2%, respectively, versus control cells; P < 0.05). Apoptosis and G1 phase arrest (G1 phase percentages: 76.1 ± 2.9% and 79.9 ± 1.8% respectively, versus control cells 65.9 ± 4.9%; P < 0.05) correlated with increased p53 and p21 levels and caspase 3 activity, and decreased cyclin D1 and Bcl-2-family protein levels (P < 0.05, all cases). These findings suggest that Monascus-fermented products may represent a novel, protective strategy against alcoholic liver disease by attenuating oxidative stress, inflammatory response, steatosis and inhibit heaptic stellate cell proliferation.
參考文獻
劉新裕、王昭月、徐原田、宋麗梅。1995。本省山藥之研究。中醫藥雜誌。6: 111-126。
劉新裕、張同吳、林義恭、陳淑芬、王昭月、朱戩良、王順成。1999。山藥之品種特性、生產潛力、物化性質與抗氧化研究。中華農業研究。48: 1-22。
許雅雯。2011。紅麴Monascus purpureus NTU568發酵產物中防癌及其相關活性成分之研究。國立台灣大學生命科學院生化科技系博士論文。
劉新裕、王昭月、宋麗梅、徐原田。1994。重要藥用植物之生產與品質研究。中醫藥雜誌。5: 167-183。
劉新裕、張同吳、林義恭、王昭月。2000b。優良保健植物山藥之開發與利用。行政院農業委員會農業試驗所編印。台中。